Why The War On Cancer Hasn't Been Won : Shots - Health News Medical researchers have made only modest progress treating the most common cancers since the war on cancer was declared in 1971. The disease has proved far more complicated than doctors had hoped.
NPR logo

Why The War On Cancer Hasn't Been Won

  • Download
  • <iframe src="https://www.npr.org/player/embed/394132747/394906617" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript
Why The War On Cancer Hasn't Been Won

Why The War On Cancer Hasn't Been Won

  • Download
  • <iframe src="https://www.npr.org/player/embed/394132747/394906617" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript

AUDIE CORNISH, HOST:

This week we pick up our series Living Cancer, which is produced with member station WNYC. Today, where things stand in research some 44 years since President Richard Nixon famously declared a war on cancer. There's been progress, but cancer is still a major killer. More than half a million Americans will die of it this year. Death rates have been falling slowly over the past decade, and that's one measure of progress. Progress can also be measured in how well scientists understand the disease. NPR's Richard Harris explores that.

RICHARD HARRIS, BYLINE: Robert Weinberg is a luminary in the world of cancer. He's a biologist at MIT and founding member of the Whitehead Institute for Biomedical Research. Last year he wrote a provocative essay in the journal Cell arguing that the conceptual understanding of cancer has come full circle over the past few decades. He starts his argument from the viewpoint of scientists in the 1950s.

ROBERT WEINBERG: Cancer was an extremely complicated process that needed to be described in hundreds, if not thousands, of different ways.

HARRIS: Then scientists started glimpsing what they thought were simplifying principles. The first idea - which helped spur the government's war on cancer - was that viruses were the prime drivers of human cancers. That proved not to be the case. And as that idea faded, it was replaced by the notion that cancer is all about wayward genes.

WEINBERG: The thought, at least in the early 1980s, was that there were a small number of these mutant cancer-causing oncogenes, and therefore that one could understand a whole disparate group of cancers simply by studying these mutant genes that seemed to be present in many of them. And this gave the notion, the illusion over the ensuing years, that we would be able to understand the laws of cancer formation the way we understand, with some simplicity, the laws of physics, for example.

HARRIS: But as scientists delved into cancer genes, Weinberg says the simplicity - the unifying principles - gradually evaporated.

WEINBERG: Over the last 10 to 15 years we began to accumulate once again an overwhelming mass of information that cancer is indeed a highly complex process, and that attempts at distilling it down to a small number of simple processes may not really work that easily. And so we are once again caught in this quandary: How can we understand this complexity in terms of a small number of underlying basic principles?

VICTOR VELCULESCU: I think it may have been wishful thinking to think that a disease like cancer was simple to begin with.

HARRIS: Victor Velculescu has been pondering these same deep questions as a top cancer researcher at Johns Hopkins University. Talk about complexity - it's become clear that cancer isn't a single disease or even a hundred different diseases.

VELCULESCU: Between everybody that has cancer today, to everybody that's probably ever had cancer since the beginning of humankind, has had different molecular alterations in this disease.

HARRIS: So you could say that every case of cancer is a unique disease.

VELCULESCU: The other complicating thing is that cancers aren't static. They actually change over time.

HARRIS: Change within each patient. That's why a treatment that works for a while often loses its punch and doctors have to search for some other treatment. These bedside observations match what scientists had been discovering in the lab. Velculescu says there aren't just a few so-called cancer genes. It turns out many genes can be damaged and can contribute to the process of malignancy.

VELCULESCU: But it also became clear that we could simplify these genetic changes into certain pathways.

HARRIS: Pathways are something like assembly lines within the cells - the chemical steps that keep the cells alive and functioning. Each gene creates a station along that assembly line. Scientists have discovered that there are many different ways for these pathways to break down, leading to cancer.

VELCULESCU: And some of them were pathways that people had been thinking were important in cancer and some were totally new.

HARRIS: Those pathways, both old and new, provide potential places to block the progress of cancer with drugs. The drug Gleevec, for example, blocks just one pathway and stops certain cancers. Other drugs block other pathways, not as dramatically but still with benefit to patients, like the drug Ibrance, recently approved for certain types of breast cancer.

Bill Nelson, who heads the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, says finding these pathways and then identifying drugs that will block them has been a big step up from simple trial and error.

BILL NELSON: And so it's made for a much more cost-efficient and time-efficient process, and you really are seeing a lot of drugs appear now to treat different cancers.

HARRIS: But here's where the complex reality of cancer raises its head again. Only rarely can a single drug block a single pathway and, by so doing, stop a cancer. Nelson expects that most cancers will require a combination of drugs.

NELSON: If we'll need treatment combinations, how many combinations will we need?

HARRIS: There aren't simply a dozen pathways or even a few hundred. Nobody has found them all, but there are potentially thousands.

NELSON: It's hard to imagine taking a thousand different agents. I don't think that's what we'll end up with. But I think it's a real question as you look forward.

HARRIS: And this can get expensive quickly, especially if drug companies keep setting prices around $100,000 a year for each new therapy. Challenges in cancer treatment go far beyond the biological complexity. And that brings us back to Robert Weinberg's essay. He's actually not defeated by the notion that the intellectual framework for understanding cancer has come full circle. After all, over these 40 years, many ideas have flowed from labs and lead to incremental advances in treating cancer.

WEINBERG: The war on cancer will not be won in one dramatic battle. It will be a series of skirmishes.

HARRIS: In fact, that's how the war on cancer has been waged all along. Richard Harris, NPR News.

CORNISH: Our series is produced with WNYC and with "Ken Burns Presents: Cancer: The Emperor Of All Maladies." It will air on PBS station starting next week.

Copyright © 2015 NPR. All rights reserved. Visit our website terms of use and permissions pages at www.npr.org for further information.

NPR transcripts are created on a rush deadline by Verb8tm, Inc., an NPR contractor, and produced using a proprietary transcription process developed with NPR. This text may not be in its final form and may be updated or revised in the future. Accuracy and availability may vary. The authoritative record of NPR’s programming is the audio record.